RU2016125752A - Соединение семейства авермектина или семейства мильбемицина для лечения и/или профилактики атопического дерматита - Google Patents
Соединение семейства авермектина или семейства мильбемицина для лечения и/или профилактики атопического дерматита Download PDFInfo
- Publication number
- RU2016125752A RU2016125752A RU2016125752A RU2016125752A RU2016125752A RU 2016125752 A RU2016125752 A RU 2016125752A RU 2016125752 A RU2016125752 A RU 2016125752A RU 2016125752 A RU2016125752 A RU 2016125752A RU 2016125752 A RU2016125752 A RU 2016125752A
- Authority
- RU
- Russia
- Prior art keywords
- family
- pharmaceutical composition
- composition
- use according
- compound
- Prior art date
Links
- 239000005660 Abamectin Substances 0.000 title claims 9
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 title claims 8
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 title claims 6
- 206010012438 Dermatitis atopic Diseases 0.000 title claims 4
- 201000008937 atopic dermatitis Diseases 0.000 title claims 4
- 230000002265 prevention Effects 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims 3
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 229960002418 ivermectin Drugs 0.000 claims 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 239000005918 Milbemectin Substances 0.000 claims 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 1
- 229950008167 abamectin Drugs 0.000 claims 1
- 125000005250 alkyl acrylate group Chemical group 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229940073669 ceteareth 20 Drugs 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 229960002303 citric acid monohydrate Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229940008099 dimethicone Drugs 0.000 claims 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- 239000004205 dimethyl polysiloxane Substances 0.000 claims 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims 1
- 229960003997 doramectin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- CXEGAUYXQAKHKJ-NSBHKLITSA-N emamectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](NC)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 CXEGAUYXQAKHKJ-NSBHKLITSA-N 0.000 claims 1
- DXIOOXFZLKCVHK-UTAOKEBVSA-N emamectin B1b Chemical compound C1[C@H](OC)[C@@H](NC)[C@H](C)O[C@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C DXIOOXFZLKCVHK-UTAOKEBVSA-N 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 claims 1
- 229960002346 eprinomectin Drugs 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- HICUREFSAIZXFQ-JOWPUVSESA-N i9z29i000j Chemical compound C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\[C@H](OC(=O)C(=N/OC)\C=1C=CC=CC=1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 HICUREFSAIZXFQ-JOWPUVSESA-N 0.000 claims 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 claims 1
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 claims 1
- 229940099245 milbemycin oxime Drugs 0.000 claims 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims 1
- 229960004816 moxidectin Drugs 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- YNFMRVVYUVPIAN-UHFFFAOYSA-N nemadectin alpha Natural products C1C(O)C(C)C(C(C)=CC(C)C)OC11OC(CC=C(C)CC(C)C=CC=C2C3(C(C(=O)O4)C=C(C)C(O)C3OC2)O)CC4C1 YNFMRVVYUVPIAN-UHFFFAOYSA-N 0.000 claims 1
- 229940055577 oleyl alcohol Drugs 0.000 claims 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 1
- 229960005323 phenoxyethanol Drugs 0.000 claims 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 1
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 claims 1
- 229960002245 selamectin Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000001587 sorbitan monostearate Substances 0.000 claims 1
- 229940035048 sorbitan monostearate Drugs 0.000 claims 1
- 235000011076 sorbitan monostearate Nutrition 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (14)
1. Фармацевтическая композиция, включающая соединение семейства авермектина или семейства мильбемицина в фармацевтически приемлемом носителе, для применения в лечении и/или профилактике атопического дерматита.
2. Фармацевтическая композиция для применения по п.1, где соединение семейства авермектина выбрано из группы, состоящей из ивермектина, авермектина, абамектина, дорамектина, эприномектина и селамектина, аверсектина В, АВ или С, эмамектина В1а, эмамектина В1b и их производных.
3. Фармацевтическая композиция для применения по п.2, где соединение семейства авермектина представлено ивермектином.
4. Фармацевтическая композиция для применения по п.1, где соединение семейства мильбемицина выбрано из группы, состоящей из лепимектина, мильбемектина, мильбемицина оксима и моксидектина, 6’-этиллепимектина, 6’-метиллепимектина и их производных или немадектина α, β, γ или δ.
5. Фармацевтическая композиция для применения по любому из пп.1-4 в лечении и/или профилактике атопического дерматита у беременных женщин, детей и младенцев.
6. Фармацевтическая композиция для применения по п.5 в лечении и/или профилактике атопического дерматита у младенцев.
7. Фармацевтическая композиция для применения по любому из пп.1-6, где композиция вводится путем местного нанесения.
8. Фармацевтическая композиция для применения по любому из пп.1-7, где композиция находится в форме эмульсии, крема, лосьона, геля или раствора.
9. Фармацевтическая композиция для применения по любому из пп.1-8, где композиция включает 0,001-5%, более предпочтительно 0,001-1% массовой доли соединения семейства авермектина или семейства мильбемицина относительно общей массы композиции.
10. Фармацевтическая композиция для применения по п.9, где композиция содержит в водном растворе:
как % от массы относительно общей массы композиции.
11. Фармацевтическая композиция для применения по п.9, где композиция содержит 0,001-0,3% массовой доли соединения семейства авермектина или семейства мильбемицина относительно общей массы композиции.
12. Фармацевтическая композиция для применения по п.10, где композиция содержит 0,001-0,05% массовой доли соединения семейства авермектина или семейства мильбемицина относительно общей массы композиции.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306633 | 2013-11-29 | ||
| EP13306633.2 | 2013-11-29 | ||
| PCT/EP2014/075927 WO2015079016A1 (en) | 2013-11-29 | 2014-11-28 | Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018135676A Division RU2792693C2 (ru) | 2013-11-29 | 2014-11-28 | Соединение семейства авермектина или семейства мильбемицина для лечения и/или профилактики атопического дерматита |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016125752A true RU2016125752A (ru) | 2018-01-09 |
| RU2669942C1 RU2669942C1 (ru) | 2018-10-17 |
Family
ID=49713042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016125752A RU2669942C1 (ru) | 2013-11-29 | 2014-11-28 | Соединение семейства авермектина или семейства мильбемицина для лечения и/или профилактики атопического дерматита |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170000812A1 (ru) |
| EP (1) | EP3074021B1 (ru) |
| JP (2) | JP6448641B2 (ru) |
| KR (1) | KR102341441B1 (ru) |
| CN (1) | CN105916511A (ru) |
| AU (1) | AU2014356444B2 (ru) |
| CA (1) | CA2930909A1 (ru) |
| MX (1) | MX370957B (ru) |
| RU (1) | RU2669942C1 (ru) |
| WO (1) | WO2015079016A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11234959B2 (en) * | 2016-11-03 | 2022-02-01 | Galderma Holding SA | Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema |
| WO2020021670A1 (ja) * | 2018-07-26 | 2020-01-30 | マルホ株式会社 | 液状外用剤 |
| WO2020161771A1 (ja) * | 2019-02-04 | 2020-08-13 | マルホ株式会社 | 皮膚用組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0820525B2 (ja) | 1986-12-01 | 1996-03-04 | 防衛庁技術研究本部長 | 磁気補償装置 |
| US6399651B1 (en) * | 2000-06-29 | 2002-06-04 | L. Dean Parks | Method of treating dermatoses using avermectin compound |
| JP2004168763A (ja) | 2002-10-30 | 2004-06-17 | Dsr Corp | 皮膚化粧料 |
| FR2854074B1 (fr) | 2003-04-24 | 2007-11-23 | Galderma Res & Dev | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques |
| JP5711867B2 (ja) | 2003-04-24 | 2015-05-07 | ガルデルマ・ソシエテ・アノニム | 皮膚科学的疾患の治療のためのアイバメクチンの使用 |
| WO2005077349A1 (ja) | 2004-02-17 | 2005-08-25 | Otsuka Pharmaceutical Co., Ltd. | ヒトβディフェンシン産生促進剤 |
| FR2867684B1 (fr) * | 2004-03-18 | 2006-05-05 | Galderma Sa | Gel creme contenant de l'ivermectine |
| DE602005020912D1 (de) | 2004-03-18 | 2010-06-10 | Galderma Sa | Ivermectin enthaltende creme |
| FR2883181B1 (fr) | 2005-03-17 | 2007-05-18 | Galderma Sa | Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee |
| FR2891460B1 (fr) | 2005-09-30 | 2010-07-30 | Galderma Sa | Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum. |
| EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| FR2906467B1 (fr) * | 2006-09-28 | 2012-11-09 | Galderma Sa | Utilisation de composes de la famille des milbemycines pour le traitement de desordres dermatologiques chez l'homme |
| FR2907012B1 (fr) | 2006-10-12 | 2012-09-21 | Galderma Sa | Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation |
| WO2008101968A2 (en) * | 2007-02-20 | 2008-08-28 | Galderma Research & Development | A method for delivery of a therapeutic substance into the skin |
| JP2012513387A (ja) * | 2008-12-23 | 2012-06-14 | ガルデルマ・ソシエテ・アノニム | 感水性の活性成分を含む、局所用医薬組成物 |
| FR2942138A1 (fr) * | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | Association de composes pour le traitement ou la prevention des affections dermatologiques |
| US8897218B2 (en) | 2010-10-18 | 2014-11-25 | Verizon Patent And Licensing Inc. | Femtocell location encoding |
| JPWO2014017319A1 (ja) * | 2012-07-26 | 2016-07-11 | 国立大学法人京都大学 | フィラグリン産生促進剤、フィラグリン産生低下に伴う疾患治療剤及び当該治療剤のスクリーニング方法 |
| US9233117B2 (en) | 2013-07-08 | 2016-01-12 | Galderma S. A. | Treatment of inflammatory lesions of rosacea with ivermectin |
-
2014
- 2014-11-28 CA CA2930909A patent/CA2930909A1/en not_active Abandoned
- 2014-11-28 WO PCT/EP2014/075927 patent/WO2015079016A1/en active Application Filing
- 2014-11-28 EP EP14809609.2A patent/EP3074021B1/en active Active
- 2014-11-28 CN CN201480065423.XA patent/CN105916511A/zh active Pending
- 2014-11-28 KR KR1020167016533A patent/KR102341441B1/ko active IP Right Grant
- 2014-11-28 AU AU2014356444A patent/AU2014356444B2/en not_active Ceased
- 2014-11-28 RU RU2016125752A patent/RU2669942C1/ru active IP Right Revival
- 2014-11-28 US US15/100,302 patent/US20170000812A1/en not_active Abandoned
- 2014-11-28 JP JP2016535011A patent/JP6448641B2/ja not_active Expired - Fee Related
- 2014-11-28 MX MX2016006927A patent/MX370957B/es active IP Right Grant
-
2017
- 2017-07-12 US US15/648,055 patent/US10398720B2/en active Active
-
2018
- 2018-11-28 JP JP2018222176A patent/JP6667602B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6448641B2 (ja) | 2019-01-09 |
| JP6667602B2 (ja) | 2020-03-18 |
| RU2018135676A (ru) | 2018-11-19 |
| RU2669942C1 (ru) | 2018-10-17 |
| WO2015079016A1 (en) | 2015-06-04 |
| MX2016006927A (es) | 2016-10-28 |
| MX370957B (es) | 2020-01-09 |
| US20170000812A1 (en) | 2017-01-05 |
| RU2018135676A3 (ru) | 2022-02-09 |
| US20170304340A1 (en) | 2017-10-26 |
| KR20160082254A (ko) | 2016-07-08 |
| CA2930909A1 (en) | 2015-06-04 |
| EP3074021A1 (en) | 2016-10-05 |
| AU2014356444A1 (en) | 2016-06-09 |
| US10398720B2 (en) | 2019-09-03 |
| JP2019031572A (ja) | 2019-02-28 |
| KR102341441B1 (ko) | 2021-12-24 |
| JP2016538311A (ja) | 2016-12-08 |
| EP3074021B1 (en) | 2021-05-12 |
| CN105916511A (zh) | 2016-08-31 |
| AU2014356444B2 (en) | 2019-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2531087C2 (ru) | Комбинация авермектина или милбемицина с адренергическими рецепторами для лечения или профилактики дерматологических заболеваний | |
| CA2992352C (en) | Stuffy nose deblocking composition having antiviral activity | |
| RU2016103753A (ru) | Лечение воспалительных повреждений при розациа с помощью ивермектина | |
| EA201291249A1 (ru) | Пероральные лекарственные формы бендамустина и их терапевтическое применение | |
| WO2010063476A3 (en) | Solid dosage forms of bendamustine | |
| RU2016125752A (ru) | Соединение семейства авермектина или семейства мильбемицина для лечения и/или профилактики атопического дерматита | |
| RU2011146232A (ru) | Крем медицинского назначения, изготовленный с использованием сульфадиазина серебра и хитозана и способ его изготовления | |
| ES2932262T3 (es) | Composición para la prevención o el tratamiento de cáncer de ovario metastásico, cáncer de endometrio o cáncer de mama | |
| RU2014142038A (ru) | Короткие антимикробные липопептиды | |
| US20210128518A1 (en) | Cannabinoid-containing dermatological compositions and methods using same | |
| AU2013234122A1 (en) | Polypeptides and their use | |
| US11517600B2 (en) | Use of Crassocephalum rabens extract in the treatment of breast cancer | |
| US8901091B2 (en) | Method of treating herpes virus infection using macrocyclic lactone compound | |
| WO2015053636A1 (en) | Veterinary formulations and methods | |
| US8901090B2 (en) | Method of treating otitis externa using macrocyclic lactone compound | |
| NZ619290A (en) | Anthelmintic formulation | |
| GB2567285A (en) | Preparation for nasal-nasopharyngeal treatment | |
| EP2762146A1 (en) | Composition for Earache | |
| CN104739854A (zh) | Nac与壳聚糖复方含漱液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20191129 |
|
| NF4A | Reinstatement of patent |
Effective date: 20210203 |